Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Determination of EBV serostatus prior to kidney transplantation: comparison of VIDAS®, LIAISON® and immunofluorescence assays.

Johannessen I, Noel M, Galloway A, Black S, Shearman M, Graham C.

J Virol Methods. 2014 Jul;203:107-11. doi: 10.1016/j.jviromet.2014.03.022. Epub 2014 Apr 2.

PMID:
24704349
[PubMed - in process]
2.

Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.

Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.

Nephrol Dial Transplant. 2012 Jul;27(7):2971-9. doi: 10.1093/ndt/gfr769. Epub 2012 Jan 24.

PMID:
22273720
[PubMed - indexed for MEDLINE]
Free Article
3.

Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status.

Lupo J, Germi R, Semenova T, Buisson M, Seigneurin JM, Morand P.

Clin Vaccine Immunol. 2012 Jun;19(6):929-34. doi: 10.1128/CVI.00100-12. Epub 2012 Apr 25.

PMID:
22539474
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cytomegalovirus & Epstein Barr Virus serostatus as a predictor of the long-term outcome of kidney transplantation.

Le Page AK, Mackie FE, McTaggart SJ, Kennedy SE.

Nephrology (Carlton). 2013 Dec;18(12):813-9. doi: 10.1111/nep.12149.

PMID:
23927085
[PubMed - in process]
5.
6.

Comparison of the performance of the LIAISON VZV-IgG and VIDAS automated enzyme linked fluorescent immunoassays with reference to a VZV-IgG time-resolved fluorescence immunoassay and implications of choice of cut-off for LIAISON assay.

Maple PA, Rathod P, Smit E, Gray J, Brown D, Boxall EH.

J Clin Virol. 2009 Jan;44(1):9-14. doi: 10.1016/j.jcv.2008.08.012. Epub 2008 Sep 27.

PMID:
18823815
[PubMed - indexed for MEDLINE]
7.

Performance of new enzyme-linked fluorescent assays for detection of Epstein-Barr virus specific antibodies in routine diagnostics.

Koidl C, Riedl R, Schweighofer B, Fett S, Bozic M, Marth E.

Wien Klin Wochenschr. 2011 Apr;123(7-8):230-4. doi: 10.1007/s00508-011-1561-z. Epub 2011 Mar 31.

PMID:
21451951
[PubMed - indexed for MEDLINE]
8.
9.

[Performance of the VIDAS automated immunoassay for the determination of Epstein-Barr virus serological status].

De Ory F, Guisasola ME, Sanz JC, García-Bermejo I.

Enferm Infecc Microbiol Clin. 2012 Dec;30(10):618-20. doi: 10.1016/j.eimc.2012.06.001. Epub 2012 Jul 31. Spanish.

PMID:
22854635
[PubMed - indexed for MEDLINE]
10.
11.

Comparison of the Vidas system and two recent fully automated assays for diagnosis and follow-up of toxoplasmosis in pregnant women and newborns.

Murat JB, Dard C, Fricker Hidalgo H, Dardé ML, Brenier-Pinchart MP, Pelloux H.

Clin Vaccine Immunol. 2013 Aug;20(8):1203-12. doi: 10.1128/CVI.00089-13. Epub 2013 Jun 5.

PMID:
23740928
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Association between Epstein-Barr virus seroconversion and immunohistochemical changes in tonsils of pediatric solid organ transplant recipients.

Shapiro NL, Tang CG, Bhattacharyya N.

Laryngoscope. 2011 Aug;121(8):1718-25. doi: 10.1002/lary.21871.

PMID:
21792960
[PubMed - indexed for MEDLINE]
13.

Epstein-Barr virus infection after kidney transplantation.

Kaden J, Petersen S, Kaden K, May G.

Transpl Int. 1998;11 Suppl 1:S119-24.

PMID:
9664960
[PubMed - indexed for MEDLINE]
14.

Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.

Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy J.

Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1712-7.

PMID:
8970360
[PubMed - indexed for MEDLINE]
15.

Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method.

Gärtner BC, Hess RD, Bandt D, Kruse A, Rethwilm A, Roemer K, Mueller-Lantzsch N.

Clin Diagn Lab Immunol. 2003 Jan;10(1):78-82.

PMID:
12522043
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma.

Opelz G, Daniel V, Naujokat C, Döhler B.

Transplantation. 2009 Oct 27;88(8):962-7. doi: 10.1097/TP.0b013e3181b9692d.

PMID:
19855238
[PubMed - indexed for MEDLINE]
17.

Is screening for IgG antibody to cytomegalovirus and Epstein-Barr virus infections mandatory in potential renal transplant recipients and donors in Iran?

Saghafi H, Qorashi M, Heidari A.

Transplant Proc. 2009 Sep;41(7):2761-3. doi: 10.1016/j.transproceed.2009.07.057.

PMID:
19765428
[PubMed - indexed for MEDLINE]
18.

Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States.

Quinlan SC, Pfeiffer RM, Morton LM, Engels EA.

Am J Hematol. 2011 Feb;86(2):206-9. doi: 10.1002/ajh.21911.

PMID:
21264909
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients.

Tsai DE, Nearey M, Hardy CL, Tomaszewski JE, Kotloff RM, Grossman RA, Olthoff KM, Stadtmauer EA, Porter DL, Schuster SJ, Luger SM, Hodinka RL.

Am J Transplant. 2002 Nov;2(10):946-54.

PMID:
12482147
[PubMed - indexed for MEDLINE]
Free Article
20.

Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation.

Harwood JS, Gould FK, McMaster A, Hamilton JR, Corris PA, Hasan A, Gennery AR, Dark JH.

Pediatr Transplant. 1999 May;3(2):100-3.

PMID:
10389130
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk